Biosimilar Insights
-
Precision Radiopharmaceuticals with Ratio's Jack Hoppin, Ph.D.
2/21/2024
Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment for players in the space to put on a precision medicine clinic, so to speak. What’s more, Radiopharmaceuticals create a unique business opportunity given the closely related and necessary companion diagnostic arena.
-
The Use Of Injectable Packaging From Early Development To Commercialization
2/20/2024
While in their early-stage development of a mAb biosimilar for oncology treatment, a large biopharmaceuticals company sought a packaging recommendation: a stopper to maintain high-quality standards.
-
The 10 Most Frequently Asked Questions On Glass: Part 2
2/20/2024
Read the second part of this series on the most common questions encountered by an expert focused in scientific affairs and technical solutions for glass.
-
Managing Mergers With Sail's Guillaume Pfefer, Ph.D
2/15/2024
You might be aware that Sail Biomedicines was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger was executed, how the two companies are integrating their talent, IP, and resources, and what Sail Biomedicines CEO Dr. Guillaume Pfefer and team are currently doing to take the fruits of the company’s platform into the clinic.
-
Managing Mergers With Sail's Guillaume Pfefer, Ph.D.
2/15/2024
While you might be aware that Sail Biomedicines was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger was executed, how the two companies are integrating their talent, IP, and resources, and what Sail Biomedicines CEO Dr. Guillaume Pfefer and team are currently doing to take the fruits of the company’s platform into the clinic.
-
The Cure For The Cure
2/14/2024
Traditional aseptic filling solutions can introduce contamination and variability. Learn about Cytiva's commitment to finding innovative solutions and improving patient outcomes in the field of medicine.
-
A New Reality In Life Sciences
2/14/2024
Gain insight from this author's experience with virtual reality (VR) and the specific benefits of VR in scientific contexts.
-
Big Risks Yield Great Rewards In Cell Therapy
2/14/2024
George White, Cytiva’s GM of Product Management for Cell and Gene Therapy, provides insight into the latest developments and strategies in cell therapy and where this dynamic field is headed.
-
Finding The Talent To Fuel Biopharma Breakthroughs
2/13/2024
Explore findings from research into talent pool resilience in the biopharmaceutical industry that incorporate survey insights as well as external data to ensure a more accurate overview.
-
Consolidating The Supply Chain For mRNA
2/12/2024
Learn about the first end-to-end cGMP facility that was developed for mRNA manufacturing to address the shortage of CDMOs and the inadequate and inefficient supply chain options for sourcing GMP mRNA.